AACR President-elect to host press conference on cancer risk factors and genetics

NewsGuard 100/100 Score

As cancer continues to affect one in two men and one in three women, researchers are increasing their knowledge on the known risk factors for cancer both environmentally and genetically.

At the AACR 102nd Annual Meeting 2011, which will be held here April 2-6, AACR President-elect Judy Garber, M.D., director of the center for cancer genetics and prevention at the Dana-Farber Cancer Institute, will host a press conference on cancer risk factors and genetics that will feature the following research:

•BRCA2 Mutations Associated with Improved Survival for Ovarian Cancer
•AIDS Associated With an Increased Risk of Some Stomach, Esophageal Cancers
•Bad Mix: Heavy Beer Drinking and a Gene Variant Increases Gastric Cancer Risk
•Study Confirms Genetic Differences in Breast Tissue Among Races

The press conference will take place on Monday, April 4 at 11:00 a.m. ET in room W313 of the Orange County Convention Center. Reporters who cannot attend in person can participate using the following information:

•U.S. & Canada: (888) 647-7462
•International: (201) 604-0169
•Access Code: 244091

Source: American Association for Cancer Research

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy